Table 4. Evaluation of reduced glutathione (GSH) and thiobarbituric-acid-reactive substances (TBARS) in the kidney of Wistar rats treated with CMN SD, unmodified CMN, cDDP or their associations.
| Treatments | GSH (nmol/mg protein) | TBARS(nmol/mg protein) |
|---|---|---|
| Saline solution | 18.9 ± 0.4 | 0.249 ± 0.011 |
| GLA | 17.7 ± 2.6 | 0.226 ± 0.023 |
| CMN SD 5 | 14.2 ± 1.3 | 0.237 ± 0.018 |
| CMN SD 25 | 15.3 ± 1.1 | 0.232 ± 0.026 |
| CMN SD 50 | 17.2 ± 1.7 | 0.247 ± 0.018 |
| CMN 50 | 14.4 ± 1.2 | 0.236 ± 0.018 |
| cDDP | 15.2 ± 3.5 | 0.302 ± 0.026* |
| GLA + cDDP | 18.5 ± 0.6 | 0.286 ± 0.014* |
| CMN SD 5 + cDDP | 16.6 ± 1.3 | 0.215 ± 0.009# |
| CMN SD 25 + cDDP | 14.0 ± 1.7 | 0.200 ± 0.011# |
| CMN SD 50 + cDDP | 19.1 ± 2.5* # | 0.218 ± 0.018# |
| CMN 50 + cDDP | 17.0 ± 1.4 | 0.222 ± 0.064# |
Saline solution or cDDP was administered intraperitoneally 30 min after the last gavage of CMN SD or unmodified CMN. cDDP: cisplatin (6 mg/kg b.w.); CMN: curcumin (5, 25 and 50 mg/kg b.w.); GLA: gelucire®50-13/aerosil®; SD: solid dispersion. The results represent the mean ± standard deviation for each group (six animals/group).
*
Significantly different from saline solution and GLA groups.
#
Significantly different from cDDP group, assessed by ANOVA and Tukey’s post hoc test (p < 0.05).